Comparative Pharmacology
Head-to-head clinical analysis: SPECTRACEF versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPECTRACEF versus TAZICEF.
SPECTRACEF vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
400 mg orally twice daily for 10-14 days.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic